Peregrine Pharmaceuticals Announces Four Upcoming Presentations at the American Association for Cancer Research 2008 Annual Meeting

Saturday, April 12, 2008 General News J E 4
TUSTIN, Calif., April 11 PeregrinePharmaceuticals, Inc. (Nasdaq: PPHM), a clinical stage biopharmaceuticalcompany developing targeted therapies for the treatment of cancer andhepatitis C virus infection (HCV), today announced that the followingpreclinical abstracts will be the subject of oral and poster presentations atthe 2008 Annual Meeting of the American Association for Cancer Research(AACR), being held April 12-16, 2008 in San Diego:

Abstracts and information about the AACR and its Annual Meeting may befound at

About Peregrine Pharmaceuticals

Peregrine Pharmaceuticals, Inc. is a biopharmaceutical company with aportfolio of innovative product candidates in clinical trials for thetreatment of cancer and hepatitis C virus (HCV) infection. The company ispursuing three separate clinical programs in cancer and HCV infection with itslead product candidates bavituximab and Cotara(R). Peregrine also has in-housemanufacturing capabilities through its wholly owned subsidiary AvidBioservices, Inc. (, which provides development andbio-manufacturing services for both Peregrine and outside customers.Additional information about Peregrine can be found at "Targeting mutant p53 protein and tumor vasculature: An effective combination therapy for advanced breast tumors" (Abstract #2341, New Targets 1: Mechanisms Session) - Poster session scheduled for Monday, April 14, 2008 from 8:00 am to 12:00 pm. -- "An immunocytokine that binds to phosphatidylserine generates an effective cell-based tumor vaccine in mice" (Abstract #2841, Tumor Vaccines Session) - Poster session scheduled for Monday, April 14, 2008 from 1:00 pm to 5:00 pm. -- "Combination of a monoclonal anti-phosphatidylserine antibody with docetaxel strongly inhibits the growth and metastasis of hormone-refractory prostate cancers in mice" (Abstract #2551, New Approaches to Biological Therapy Session) - Oral presentation scheduled for Monday, April 14, 2008 at 2:10 pm. -- "Antibody targeting of phosphatidylserine produces a cytokine microenvironment that enhances innate anti-tumor immune responses" (Abstract #4079, Immunoconjugates, Peptides, and Protein Therapeutics Session) - Poster session scheduled for Tuesday, April 15, 2008 from 8:00 am to 12:00 pm.

SOURCE Peregrine Pharmaceuticals, Inc.


You May Also Like

View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
ABR-Affinity BioReagents to Participate in the Ame...
Remarks by the First Lady at Robert S. Folsom Lead...